• info@heparegenix.com
  • +49 (0)7071 7912810
  • Sitemap
  • Site Notice
  • Privacy Policy
HepaRegeniX GmbH
  • Home
  • About us
  • Investors
  • Science
    • Liver diseases face an enormous unmet medical need
    • MKK4 – A First-in-class Therapeutic Target
    • Translation into the Clinic
  • Jobs
  • News
  • Contact
Search
  • Home
  • About us
  • Investors
  • Science
    • Liver diseases face an enormous unmet medical need
    • MKK4 – A First-in-class Therapeutic Target
    • Translation into the Clinic
  • Jobs
  • News
  • Contact

HepaRegeniX to present key results on MKK4 inhibitors and their therapeutic efficacy at upcoming scientific conferences

p3889712021-12-29T10:46:15+01:00

New data supporting therapeutic potential of MKK4 inhibition in advanced liver diseases.

11/04/2021
By p3889712021, Press releaseComments Off
Read more...

HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute

p3889712021-12-29T10:47:53+01:00

HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination therapy.

10/20/2021
By p3889712021, Press releaseComments Off
Read more...

HepaRegeniX initiates first-in-man Phase 1 trial for its lead MKK4 inhibitor HRX‑0215

p3889712021-12-29T10:37:24+01:00

HRX-0215 is the first compound from the company´s small molecule-based drug discovery platform ready for clinical testing.

08/10/2021
By p3889712021, Press releaseComments Off
Read more...
Get In Touch
HepaRegeniX GmbH: Logo

HepaRegeniX has successfully discovered and developed several drug candidates to combat multiple liver diseases. The first candidate HRX-0215 has recently entered clinical development.

Get in touch

Phone: +49 (0)7071 7912810
Fax: +49 (0)7071 7912809
E-mail: info@heparegenix.com

Address

HepaRegeniX GmbH
Eisenbahnstraße 63
72072 Tübingen
Germany

© Copyright 2016-2020 HepaRegeniX GmbH. All Rights Reserved.